CRNX - Insider Buy (The Doc Just Bought a Bag)

Imagine this:

You’re a pharmaceutical CEO. Your hairline is holding on for dear life, your email inbox has 6,000 unread trial results, and your entire net worth rides on whether a hormone drops 2.4% in 24 weeks.

So what do you do?

You YOLO $6 million of your own cash into your own stock... AFTER the Phase 3 data is already out.

Ladies and gents, meet Dr. Scott Struthers, founder of Crinetics Pharmaceuticals and the undisputed heavyweight champ of biotech cojones.

His company’s drug, paltusotine, just crushed its Phase 3 trial, sending acromegaly symptoms into a hormonal headlock. Yet the market snoozed harder than a cat in a sauna. The stock dipped.

So what does the founder do?

He doesn’t tweet. He doesn’t call CNBC. He doesn’t beg analysts for price targets.

He buys.

Six. Million. Dollars.

At $37.33 a share. No options. No RSUs. Cold hard cash.

Now, CRNX sits at $31 — a full 17% below what the actual founder was willing to pay. Either he’s wrong, or Wall Street’s hungover from NVDA FOMO and ignoring a sleeper biotech banger.

You decide.

But don’t say you weren’t warned when this stock ends up juicing harder than Barry Bonds on hormone therapy.

⚠️ Disclaimer:

This is not financial advice. This content is for entertainment purposes only. Always do your own research before making investment decisions. If you buy this stock and it tanks, blame your own damn self — not the cartoon owl.